Skip to content
Evigrade
CriticalTriptan, selective 5HT1B/1D receptor agonist×Reversible MAO-A inhibitor (RIMA)

Updated · Methodology

Mechanism

Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of serotonin, noradrenaline and dopamine (moclobemide summary of product characteristics, SmPC, section 5.1). Eletriptan is a selective agonist of the serotonin 5-HT1B and 5-HT1D receptors (eletriptan SmPC, section 5.1). The moclobemide SmPC contraindicates triptans because MAO and cytochrome P450 (CYP) enzymes metabolise them and their plasma concentrations rise with moclobemide (section 4.5). According to the eletriptan SmPC itself, MAO does not metabolise eletriptan, so no interaction with MAO inhibitors is expected, and no formal interaction studies have been done (section 4.5). CYP3A4 is the main enzyme that metabolises eletriptan, with a small contribution from CYP2D6 (eletriptan SmPC, section 5.2). The risk of the pair comes from the effects of both drugs on serotonin transmission: the US Food and Drug Administration (FDA) eletriptan label warns that serotonin syndrome may occur, particularly with MAO inhibitors (section 5.7).

Symptoms

The documents do not describe how this particular combination presents, because the moclobemide summary of product characteristics (SmPC) contraindicates it in advance (sections 4.3 and 4.5). The main danger is serotonin syndrome: mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (hyperreflexia, poor coordination), nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (eletriptan label, US Food and Drug Administration, FDA, section 5.7). On rare occasions 5-HT1 agonists cause a marked rise in blood pressure, up to hypertensive crisis with acute organ damage (FDA eletriptan label, section 5.8). Eletriptan itself caused small, transient rises in blood pressure at doses of 60 mg or more, much more marked in older people and in people with kidney impairment (eletriptan SmPC, section 4.4).

Management

The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) lists triptans among contraindicated drugs and names eletriptan explicitly (moclobemide SmPC, sections 4.3 and 4.5). The eletriptan documents are softer. According to the Spanish SmPC, no interaction with monoamine oxidase (MAO) inhibitors is expected (section 4.5). The US Food and Drug Administration (FDA) label does not list MAO inhibitors among its contraindications but warns of serotonin syndrome with them (sections 4 and 5.7). The strictest document prevails, so do not prescribe eletriptan to people taking moclobemide. No document gives an interval between stopping one drug and starting the other. If the two drugs have nevertheless been taken together and serotonin syndrome is suspected, stop eletriptan (FDA eletriptan label, section 5.7). The moclobemide SmPC advises considering a lower moclobemide dose or stopping it, depending on how severe the symptoms are (section 4.4). Monitor blood pressure in people taking eletriptan (FDA eletriptan label, section 5.8).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Eletriptan

Other interactions with Moclobemide